Practice resources

Resources

Optune Lua NSCLC Summary Brochure 

Provides a summary of Optune Lua's mechanism of action, efficacy, and quality of life data in patients with mNSCLC after platinum-based therapy.

Patient Profiles 

Review these profiles to see if your patients with 2L+ mNSCLC could benefit from the introduction of Optune Lua together with a PD-1/PD-L1 inhibitor or docetaxel.

MyNovocure^® Brochure 

For more information on the support available to your practice and patients throughout every step of the treatment journey.

Management Guidelines for Dermatologic Adverse Events (dAEs)  

This brochure provides guidance on mitigating, monitoring, and managing dAEs for Optune Lua users.

Mechanism of Action Brochure 

See how Optune Lua uses TTFields to disrupt viability of cancer cells.

Find the answers to frequently asked questions about Optune Lua

Novocure is NOT permitted to provide medical advice to patients. All patients with medical questions will be referred back to their healthcare provider.

2L+, second line or later; mNSCLC, metastatic non–small cell lung cancer; MOA, mechanism of action; NSCLC, non–small cell lung cancer; PD-1/PD-L1, programmed cell death 1 protein/programmed cell death 1 ligand 1; TTFields, Tumor Treating Fields.

Important Safety Information

Contraindications

Do not use Optune Lua^® in patients with an electrical implant. Use of Optune Lua together with electrical implants has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions, such as a fall in blood pressure and breathing difficulty.

Warnings and Precautions

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure^®(the device manufacturer).

Do not prescribe Optune Lua for patients who are pregnant, whom you think might be pregnant, or who are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established.

The most common (≥10%) adverse events involving Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel were dermatitis, musculoskeletal pain, fatigue, anemia, dyspnea, nausea, cough, diarrhea, anorexia, pruritus, leukopenia, pneumonia, respiratory tract infection, localized edema, rash, pain, constipation, skin ulcers, and hypokalemia.

Other potential adverse effects associated with the use of Optune Lua include treatment related skin toxicity, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at the site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown or skin ulcer.

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

Indication For Use

Optune Luais intended as a treatment concurrent with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.

Please see full Instructions For Use (IFU) and Patient Information and Operation Manual (PIOM) for Optune Lua^®.

Important Safety Information

Contraindications

Do not use Optune Lua^® in patients with an electrical implant. Use of Optune Lua together with electrical implants has not been tested and may lead to malfunctioning of the implanted device.

Do not use Optune Lua in patients known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune Lua may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions, such as a fall in blood pressure and breathing difficulty.

Warnings and Precautions

Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure^®(the device manufacturer).

Do not prescribe Optune Lua for patients who are pregnant, whom you think might be pregnant, or who are trying to get pregnant, as the safety and effectiveness of Optune Lua in these populations have not been established.

The most common (≥10%) adverse events involving Optune Lua concurrent with PD-1/PD-L1 inhibitors or docetaxel were dermatitis, musculoskeletal pain, fatigue, anemia, dyspnea, nausea, cough, diarrhea, anorexia, pruritus, leukopenia, pneumonia, respiratory tract infection, localized edema, rash, pain, constipation, skin ulcers, and hypokalemia.

Other potential adverse effects associated with the use of Optune Lua include treatment related skin toxicity, allergic reaction to the adhesive or to the gel, overheating of the array leading to pain and/or local skin burns, infections at the site where the arrays make contact with the skin, local warmth and tingling sensation beneath the arrays, medical device site reaction, muscle twitching, and skin breakdown or skin ulcer.

If the patient has an underlying serious skin condition on the chest, evaluate whether this may prevent or temporarily interfere with Optune Lua treatment.

Indication For Use

Optune Luais intended as a treatment concurrent with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer who have progressed on or after a platinum-based regimen.

Please see full Instructions For Use (IFU) and Patient Information and Operation Manual (PIOM) for Optune Lua^®.